Memantine in Adult Autism Spectrum Disorder

Johns Hopkins University

Status

Terminated

Conditions

Asperger's Disorder

Pervasive Developmental Disorder NOS

Autism

Treatments

Drug: memantine

Drug: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01078844

NA_00015760

Details and patient eligibility

About

The purpose of this study is to see if memantine is helpful in managing problematic symptoms in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder not otherwise specified (NOS).

Enrollment

4 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

Participant is currently in treatment in the Johns Hopkins Bayview Medical Center (JHBMC)
Participant has a diagnosis of:
- Autistic Disorder
- Asperger's Disorder
- Pervasive Developmental Disorder (PDD) NOS
Participant meets one of the following criteria:
- CGI-S >= 4 (CGI-S: ________)
- Participant has the following problematic behaviors (at least one) that might be expected to benefit from memantine:

Exclusion criteria

The patient meets none of the following criteria (mark if absent):

Active seizures (Patients with a history of seizures, who have been seizure-free on an antiepileptic regimen for six months or more would be eligible).
Rett's Syndrome or Childhood Disintegrative Disorder
Active treatment with an acetylcholinesterase inhibitor
Prior or current treatment with memantine
Current treatment with lamotrigine
Genetic, metabolic or degenerative disorder (excepting Fragile X).
Brain malformation or known severe brain trauma
Pregnancy or breastfeeding
Glomerular Filtration Rate (GFR) < 30 mL/min